• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form AW filed by Cyteir Therapeutics Inc.

    3/21/24 4:07:00 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYT alert in real time by email
    AW 1 d809317daw.htm AW AW

    CYTEIR THERAPEUTICS, INC.

    P.O. Box 80084

    Stoneham, Massachusetts

    March 21, 2024

    VIA EDGAR

    U.S. Securities and Exchange Commission

    Division of Corporation Finance

    Office of Life Sciences

    100 F. Street, N.E.

    Washington, D.C. 20549

     

      Re:

    Cyteir Therapeutics, Inc. (the “Registrant”)

    Application for Withdrawal of Registrant’s Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-257920 filed on March 18, 2024

    Application for Withdrawal of Registrant’s Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-263607 filed on March 18, 2024

    Application for Withdrawal of Registrant’s Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-270787 filed on March 18, 2024

    Ladies and Gentlemen:

    Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended, Cyteir Therapeutics, Inc. hereby requests that the Securities and Exchange Commission (the “Commission”) withdraw the Registrant’s Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-257920, Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-263607 and Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-270787, each filed with the Commission on March 18, 2024 (collectively, the “Post-Effective Amendments”), as of the date hereof. We are requesting withdrawal of the Post-Effective Amendments filed on March 18, 2024 because of a filing error relating to the EDGAR submission type for each of the filings. Each of the Post-Effective Amendments was erroneously filed as EDGAR submission type “POS AM” rather than “S-8 POS,” as was intended. No securities were sold under any of the Post Effective Amendments.

    Cyteir Therapeutics, Inc. will concurrently file post-effective amendments to the above referenced registration statements under the correct EDGAR submission type.

    If you have any questions with respect to this matter, please contact Tara Fisher of Ropes & Gray LLP, counsel to the Registrant, at (617) 951-7000. Thank you for your assistance in this matter.

     

    Very truly yours,
    CYTEIR THERAPEUTICS, INC.
    By:  

    /s/ David Gaiero

      David Gaiero
      Chief Financial Officer and Treasurer
    Get the next $CYT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYT

    DatePrice TargetRatingAnalyst
    2/7/2022$16.00Outperform
    Northland Capital
    7/13/2021$40.00Outperform
    Wedbush
    7/13/2021$33.00Overweight
    Morgan Stanley
    7/13/2021$23.00Buy
    B of A Securities
    7/13/2021$30.00Overweight
    JP Morgan
    More analyst ratings

    $CYT
    SEC Filings

    View All

    SEC Form 15-12G filed by Cyteir Therapeutics Inc.

    15-12G - Cyteir Therapeutics, Inc. (0001662244) (Filer)

    3/29/24 6:11:57 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Cyteir Therapeutics Inc.

    S-8 POS - Cyteir Therapeutics, Inc. (0001662244) (Filer)

    3/21/24 4:17:14 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Cyteir Therapeutics Inc.

    S-8 POS - Cyteir Therapeutics, Inc. (0001662244) (Filer)

    3/21/24 4:17:45 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Leonard Braden Michael bought $503,238 worth of shares (170,589 units at $2.95) (SEC Form 4)

    4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)

    3/25/24 11:05:47 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leonard Braden Michael bought $342,469 worth of shares (113,777 units at $3.01) (SEC Form 4)

    4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)

    3/19/24 4:19:39 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Leonard Braden Michael claimed ownership of 3,704,687 shares (SEC Form 3)

    3 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)

    3/19/24 4:09:32 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Leonard Braden Michael bought $503,238 worth of shares (170,589 units at $2.95) (SEC Form 4)

    4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)

    3/25/24 11:05:47 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leonard Braden Michael bought $342,469 worth of shares (113,777 units at $3.01) (SEC Form 4)

    4 - Cyteir Therapeutics, Inc. (0001662244) (Issuer)

    3/19/24 4:19:39 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq

    Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today announced that it has formally notified The Nasdaq Stock Market ("Nasdaq") of its intent to delist the Company's common stock from the Nasdaq Global Select Market. Cyteir expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 18, 2024 and has requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on the same day. Cyteir does not expect that a trading market will develop for its common stock following suspension of trading on Nasdaq. Cyteir intends to

    3/7/24 4:30:00 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

    Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer now active and recruiting patients BT8009 initial clinical data showed a promising response and differentiated safety profile R&D Day outlined near-term strategic priorities and highlighted breadth of Bicycle® platform technology and ability to develop highly differentiated precision therapies for cancer and other diseases Stephen Sands appointed to Board of Directors Cash and cash equivalents of $526.4 million as of December 31, 2023, expected to provide financial runway into 2026 Bi

    2/20/24 7:05:00 AM ET
    $BCYC
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile

    - CYT-0851 demonstrated activity in combination with capecitabine in heavily pretreated platinum-refractory or -resistant ovarian cancer patients with a generally well tolerated safety profile - Overall disease control rate was 91% in the capecitabine combination with a median progression-free survival of 170 days Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled "Phase 1 Dose Expansion Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination

    10/12/23 7:30:00 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital initiated coverage on Cyteir Therapeutics with a new price target

    Northland Capital initiated coverage of Cyteir Therapeutics with a rating of Outperform and set a new price target of $16.00

    2/7/22 9:06:54 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Cyteir Therapeutics with a new price target

    Wedbush initiated coverage of Cyteir Therapeutics with a rating of Outperform and set a new price target of $40.00

    7/13/21 7:54:26 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Cyteir Therapeutics with a new price target

    Morgan Stanley initiated coverage of Cyteir Therapeutics with a rating of Overweight and set a new price target of $33.00

    7/13/21 7:33:21 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Leadership Updates

    Live Leadership Updates

    View All

    Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality

    Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Krisztina Nemenyi, PhD, RAC, to its leadership team as Senior Vice President of Regulatory Affairs and Quality. "Krisztina has an impressive track record of leading regulatory functions and development teams at global pharmaceutical companies to successful worldwide product registrations in oncology, demonstrating extensive knowledge of global clinical trial approval processes and requirements, strategic thinking about development plans that maximize the likelihood of successful regulatory appl

    5/3/22 9:00:00 AM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cyteir Therapeutics Inc. (Amendment)

    SC 13G/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)

    3/19/24 4:29:26 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Cyteir Therapeutics Inc. (Amendment)

    SC 13D/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)

    3/12/24 4:16:28 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cyteir Therapeutics Inc. (Amendment)

    SC 13G/A - Cyteir Therapeutics, Inc. (0001662244) (Subject)

    2/14/24 7:36:52 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYT
    Financials

    Live finance-specific insights

    View All

    Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

    - Continue to enroll in monotherapy and combination studies with CYT-0851 with potential for interim safety and efficacy data in second half 2022 - Progress achieved in key clinical milestones described in the 2021 IPO: Advanced CYT-0851 monotherapy to Phase 2 and initiated Phase 1 combination therapy study - Projected cash runway into 2024 to support planned R&D and clinical studies - Conference call and webcast scheduled for 4:30 p.m. ET on March 16, 2022 Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the fourth quarter and full year

    3/16/22 4:01:00 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022

    Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p.m. ET to discuss fourth quarter and full year 2022 financial and operational results. The live audio webcast can be accessed via the Investor Relations section of the Company's website at www.cyteir.com. The archived webcast will remain available for replay on Cyteir's website for 30 days. About Cyteir Therapeutics, Inc. Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthet

    3/9/22 4:30:00 PM ET
    $CYT
    Biotechnology: Pharmaceutical Preparations
    Health Care